ARPO Soars, GNFT's NASH Study Fails, Moderna's COVID-19 Vaccine On Fast Track

Today's Daily Dose brings you news about Aerpio Pharma's amended licensing deal with Gossamer Bio; Gamida's encouraging results from phase III study of Omidubicel malignancies; Genfit's disappointing NASH trial results; Fast Track designation for Moderna's mRNA vaccine against the novel coronavirus and NanoViricides' progress in the COVID-19 drug development program.

from RTT - Biotech https://ift.tt/3fTouY2
via IFTTT